Targeted therapies and tumor subtyping for anti-PD-1/PD-L1 treatments are important, but it is not always possible to distinguish adenocarcinoma from non-adenocarcinoma in advanced stage tumors, especially when only a small amount of tissue is available. Here, CD274 is linked to adenocarcinoma.